ABO and platelet transfusion therapy

Immunohematology

Volumn 23, Issue 1, 2007, Pages 20-33

  Cooling, Laura ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIGEN; BLOOD GROUP ABH ANTIGEN; BLOOD GROUP B ANTIGEN; BLOOD GROUP O ANTIGEN; GLYCOCONJUGATE; GLYCOSPHINGOLIPID;

ALLOIMMUNIZATION; ANTIGEN EXPRESSION; APHERESIS; BLOOD COMPATIBILITY; BLOOD DONOR; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; BONE MARROW TRANSPLANTATION; CLINICAL PRACTICE; GENETIC VARIABILITY; HUMAN; MEGAKARYOCYTE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCREENING; THROMBOCYTE TRANSFUSION;

ABO BLOOD-GROUP SYSTEM; ANTIGENS, HUMAN PLATELET; BLOOD GROUP INCOMPATIBILITY; BLOOD PLATELETS; HEMOLYSIS; HUMANS; IMMUNIZATION; MEGAKARYOCYTES; PLATELET TRANSFUSION;

EID: 34247204362     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Murphy S. ABO blood groups and platelet transfusion. Transfusion 1988;28:401-2.
2. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965;26:732-43.
3. Herman JH. Apheresis platelet transfusions: does ABO matter? Transfusion 2004;44:802-4.
4. Benjamin RJ, Antin JH. ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimenrelated toxicity. Transfusion 1999;39:1273-4.
5. Lapierre V, Mahe C, Auperin A, et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005;80:314-9.
6. Mollicone R, Caillard T, Pendu JL, et al. Expression of ABH and X (LeX) antigens on platelets and lymphocytes. Blood 1988;71:1113-9.
7. Santoso S, Kiefel V, Mueller-Eckhardt C. Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemostasis 1991;65:196-201.
8. Stockelberg D, Hou M, Rydberg L, Kutti J, Wadenvik H. Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Transfus Med 1996;6:243-8.
9. Kelton JG, Smith JW, Horsewood P, et al. ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109. J Lab Clin Med 1998;132:142-8.
10. Cooling LLW, Kelly K, Barton J, et al. Determinants of ABH expression on human blood platelets. Blood 2005;105:3356-64.
11. Tsuji T, Osawa T. Structures of the carbohydrate chains of membrane glycoproteins IIb and IIIa of human platelets. J Biochem 1986;100:1387-98.
12. Julmy F, Achermann F, Schulzki T, Carrel T, Nydegger U. Platelets of blood group A, donors express increased surface A antigen owing to apheresis and prolonged storage. Transfusion 2003;43:1378-85.
13. Devine V, Thon J, Schubert P, Serrano K, Kast J. Application of proteomics methods to the analysis of the platelet storage lesion. Vox Sang 2006; 91(Suppl 3):S34.
14. Kelton JG, Hamid C, Aker S, Blajchman M. The amount of blood group A substance on platelets is proportional to the amount in the plasma. Blood 1982;59:980.
15. Dunstan RA, Mansbach CM. Biochemical characterization of A blood group activity on human platelets. Vox Sang 1985;49:149-53.
16. 2 difference. Glycoconjugate J 1990;7:601-8.
17. Koerner TAW, Weinfeld HM, Bullard LSB, Williams LCJ. Antibodies against platelet glycosphingolipids: detection in serum by quantitative HPTLC-autoradiography and association with autoimmune and alloimmune processes. Blood 1989; 74:274-84.
18. Cooling LLW, Zhang D, Koerner TAW. Human platelets express gangliosides with LKE activity and ABH blood group activity. Transfusion 2001;41:504-16.
19. Holgersson J, Breimer ME, Samuelsson BE. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids. APMIS Suppl 1992;27:18-27.
20. Stults CL, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 1989;179:167-214.
21. Dunstan RA, Simpson MB, Knowles RW, Rosse WF. The origin of ABH antigens on human platelets. Blood 1985;65:615-9.
22. Cao Y, Merling A, Karsten U, Schwartz-Albiez R.The fucosylated histo-blood group antigen H (type 2 blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes. Glycobiology 2001;11:677-83.
23. Hosoi E, Hirose M, Hamano S. Expression levels of H-type (1,2)-fucosyltransferase gene and histoblood group ABO gene corresponding to hematopoietic cell differentiation. Transfusion 2003;43:65-71.
24. Okumura M, Morishima Y, Michinori O, et al. Expression of H-related antigen on human megakaryocytes and megakaryocyte leukemic cells. Int J Hematol 1991;54:151-8.
25. Schmitz B, Thiele J, Otto F, et al. Interactions between endogenous lectins and fucosylated oligosaccharides in megakaryocyte-dependent fibroblast growth of the normal bone marrow. Leukemia 1996;10:1604-14.
26. Sweegman S, Veenhof MA, Huijgens PC, Schuurhuis GJ, Drager AM. Regulation of megakaryocytopoiesis in an in vitro stroma model: preferential adhesion of megakaryocytic progenitors and subsequent inhibition of maturation. Exp Hematol 2000;28:401-10.
27. Han P, Guo XH, Story CJ. Enhanced expansion and maturation of megakaryocytic progenitors by fibronectin. Cytotherapy 2002;4:277-83.
28. Mossuz P, Schweitzer A, Molla A, Berthier R. Expression and function of receptors for extracellular matrix molecules in the differentiation of human megakaryocytes in vitro. Br J Haematol 1997;98:819-27.
29. Molla A, Mossuz P, Berthier R. Extracellular matrix receptors and the differentiation of human megakaryocytes in vitro. Leuk Lymphoma 1999;33:15-23.
30. Ichikawa D, Handa K, Hakomori SI. Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer 1998;76:284-9.
31. Ichikawa D, Handa K, Withers DA, Hakomori SI. Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Cancer Res 1997;57:3092-6.
32. Groupille C, Marionneau S, Bureau V, et al. 1,2-fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells. Glycobiology 2000;10:375-82.
33. Hoffman S, Zhou L, Gu Y, Davenport R, Cooling L. Delayed platelet engraftment in group O patients after autologous progenitor cell transplantation. Transfusion 2005;45:885-95.
34. 2 individuals. Transfusion 1988;28:456-9.
35. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000;96:1574-81.
36. Heal JM, Mullin A, Blumberg N. The importance of ABH antigens in platelet crossmatching. Transfusion 1989;29:514-20.
37. Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABH antigens on platelets. Blood 1993;82:993-9.
38. Jimenez TM, Patel SB, Pineda AA, Tefferi A, Owen WG. Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion 2003;43:328-34.
39. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987;70:23-30.
40. Schlichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
41. Brand A, Sintnicolaas K, Claas FH, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986;26:463-6.
42. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81:3428-34.
43. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Transfusion 1989;29:384-9.
44. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990;75:408-13.
45. Ishibashi M, Oshida M, Kurata Y, et al. Immunologic low-responder in ABO-incompatible renal transplant recipients explored by donor-specific platelet transfusion. Transplant Proc 1998;30: 2298-9.
46. Heal JM, Masel D, Blumberg N. Interaction of platelet Fc and complement receptors with circulating immune complexes involving the ABO system. Vox Sang 1996;71:205-11.
47. Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 1993;566-72.
48. Duquesnoy RJ, Anderson AJ, Tomasulo PA, Aster RH. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 1979;54:595-9.
49. Ellinger PJ, Morgan LK, Malecek AC, Chaplin H. Effect of ABO mismatching on a radioimmunoassay for platelet compatibility. Successful adsorption of ABO alloantibodies with synthetic A and B substance. Transfusion 1989;29:134-8.
50. Blumberg N, Heal JM, Rapoport A, et al. Effect of ABO-identical platelets and leukodepletion on blood utilization and costs of autologous marrow transplantation (abstract). Transfusion 1993;33: A15.
51. Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993;66: 309-14.
52. Blumberg N, Heal JM, Kirkley SA, et al. Leukodepleted-ABO identical blood components in the treatment of hematologic malignancies: a cost analysis. Am J Hematol 1995;48:108-15.
53. Heal JM, Kenmotsu N, Rowe JM, Blumberg N. A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 1994;45:189-90.
54. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004;18:149-65.
55. Blumberg N, Heal JM, Hicks GL, Risher WH. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 2001;41:790-3.
56. Blumberg N, Heal JM. ABO-mismatched platelet transfusions and clinical outcomes after cardiac surgery (letter).Transfusion 2002;42:1527-9.
57. Lin Y, Callum JL, Coovadia AS, Murphy PM. Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion 2002;42:166-72.
58. Badros A, Tricot G, Toor A, et al. ABO mismatch may effect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002;42:205-9.
59. Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 1999;39:179-87.
60. Stussi G, Halter J, Schanz U, Seebach JD. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apheresis Sci 2006;35:59-69.
61. Brecher ME, ed. Technical manual, 15th ed. Bethesda, MD: American Association of Blood Banks, 2005.
62. Gordon B, Tarantolo S, Ruby E, et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 1998;22: 999-1003.
63. West L, Pollock-Barziv SM, Diphanc AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001;344:793-800.
64. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004;78: 635-40.
65. Zoes C, Dube VE, Miller HJ, Vye MV. Anti-A1 in the plasma of platelet concentrates causing a hemolytic reaction. Transfusion 1977;17:29-32.
66. McLeod BC, Sassetti RJ, Weens JH, Vaithianathan T. Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate. Scand J Haematol 1982;28:193-6.
67. Conway LT, Scott EP Acute hemolytic transfusion reaction due to ABO incompatible plasma in a platelet apheresis concentrate (letter). Transfusion 1984;24:413-4.
68. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion 1985;25:60-2.
69. Ferguson DJ. Acute intravascular hemolysis after a platelet transfusion. Can Med Assoc J 1988;138: 523-4.
70. Reis MD, Coovadia AS. Transfusion of ABO-incompatible platelets causes severe haemolytic reaction. Clin Lab Haematol 1989;11:237-40.
71. Murphy MF, Hook S, Waters AH, et al. Acute haemolysis after ABO-incompatible platelet transfusions (letter). Lancet 1990;335:974-5.
72. Chow M-P, Yung C-H, Hu H-Y, Tzeng C-H. Hemolysis after ABO-incompatible platelet transfusion. Chin Med J (Taipei) 1991;48:131-4.
73. Mair B, Benson K. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 1998;38:51-5.
74. McManigal S, Sims KL. Intravascular hemolysis secondary to ABO incompatible platelet products. Am J Clin Pathol 1999;111:202-6.
75. Duguid JKM, Minards J, Bolton-Maggs PHB. Lesson of the week: incompatible plasma transfusions and haemolysis in children. Br Med J 1999;318: 176-7.
76. Larsson LG, Welsh VJ, Ladd DJ. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion 2000;40:902-6.
77. Valbonesi M, De Luigi MC, Lercari G, et al. Acute intravascular hemolysis in two patients transfused with dry-platelet units obtained from the same ABO incompatible donor. Int J Artif Organs 2000;23:642-6.
78. Sauer-Heilborn A, Jahagirdar B, Burns L, Scofield T, Nollet KE. Passive antibody, aggressive hemolysis: an ABO-incompatible platelet transfusion (abstract). Transfusion 2002;42(Suppl):SP304.
79. Reducing supernatant plasma of pooled platelets before administration to ABO-incompatible recipients. CBBS, e-network forum. Available at: http://www.cbbsweb.org/enf/2002/pltpoolplasma.html.
80. Gresens C, Gloster E, Wang L, Dimaio T. Acute hemolysis in a group A trauma patient who received a group O plateletpheresis unit (abstract). Transfusion 2003;43(Suppl):SP234.
81. Yeast JD, Plapp F. Fetal anemia as a response to prophylactic platelet transfusion in the management of alloimmune thrombocytopenia. Am J Obstet Gynecol 2003;189:874-6.
82. Ozturk A, Turken O, Sayan O, Atasoyu EM. Acute intravascular hemolysis due to ABO-incompatible platelet transfusion. Acta Haematol 2003;110: 211-2.
83. What is the frequency of hemolytic reactions associated with transfusion of plateletpheresis units containing ABO incompatible plasma. CBBS, e-network forum. Available at: http://www.cbbsweb.org/enf/2003/plt_aborxnfreq.html.
84. Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy. Transfusion 2004;44:805-8.
85. Angiolillo A, Luban NLC. Hemolysis following an out-of-group platelet transfusion in an 8-month-old with Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2004;26:267-9.
86. Sapatnekar S, Sharma G, Downes KA, Wiersma S, McGrath C, Yomtovian R. Acute hemolytic transfusion reaction in a pediatric patient following transfusion of apheresis platelets. J Clin Apheresis 2005;20:225-9.
87. Sadani DT, Urbaniak SJ, Bruce M, Tighes JE. Repeat ABO-incompatible platelet transfusions leading to haemolytic transfusion reaction. Transf Med 2006;16:375-9.
88. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003;17: 57-68.
89. Pietersz RNI, Engelfriet CP. Transfusion of apheresis platelets and ABO groups. Vox Sang 2005;88: 207-21.
90. College of American Pathology. Transfusion Medicine Survey (J-A). 2005.
91. Schwartz J, Delpalma H, Kapoor K, Hamilton T, Grima K. Anti-A titers in group O single donor platelets: to titer or not to titer (abstract). Transfusion 2003;43(Suppl):SP247.
92. Oza KK. ABO mismatched platelet transfusion and acute intravascular hemolysis (abstract). Transfusion 2002;42(Suppl):SP308.
93. Wagner F, Adamo W. Reduced rate of adverse reactions to plasma reduced pooled platelet units: possible role of minor incompatible transfusion (abstract). Vox Sang 2006;91(Suppl 3):P508.
94. Shanwell A, Ringden O, Wiechel B, Rumin S, Akerblom O. A study of the effect of ABO incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox Sang 1991;60:23-7.
95. Mollison PL, Engelfriet CP, Contreras M, ed. Blood transfusion in clinical medicine. 10th ed. Oxford: Blackwell Science, 1997.
96. Boothe G, Brecher ME, Root M, Robinson J, Haley R. Acute hemolysis due to passively transfused high-titer anti-B causing spontaneous in vitro agglutination. Immunohematology 1995;11:43-5.
97. The practice of transfusing out-of-type platelets. CBBS, e-network forum. Available at: http://www.cbbsweb.org/em72002/plttx_aboincompat.html.
98. de Wildt-Eggen J, Gulliksson H. In vivo and in vitro comparison of platelets stored in either synthetic media or plasma. Vox Sang 2003;84:256-64.
99. Ringwald J, Zimmerman R, Eckstein R. The new generation of platelet additive solution for storage at 22°C: development and current experience. Transfus Med Rev 2006;20:158-64.
100. de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000;40:398-403.
101. References on patient outcomes following transfusion of ABO incompatible platelets. CBBS, e-network forum. Available at: http//www.cbbsweb.org/enf/ outcome_aboinc_plt.html.
102. Chambers LA. Transfusion of plasma and platelets to neonates. In: Herman JH, Manno CS, eds. Pediatric transfusion therapy, 2002. Bethesda, MD: AABB Press, 2002:93-107.